BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26491071)

  • 1. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
    Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
    Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
    Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
    Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.
    Yeomans A; Lemm E; Wilmore S; Cavell BE; Valle-Argos B; Krysov S; Hidalgo MS; Leonard E; Willis AE; Forconi F; Stevenson FK; Steele AJ; Coldwell MJ; Packham G
    Oncotarget; 2016 Nov; 7(46):74807-74819. PubMed ID: 27579538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression.
    Pede V; Rombout A; Vermeire J; Naessens E; Mestdagh P; Robberecht N; Vanderstraeten H; Van Roy N; Vandesompele J; Speleman F; Philippé J; Verhasselt B
    PLoS One; 2013; 8(4):e60275. PubMed ID: 23560086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
    Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL
    Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR engagement in CLL: when translation goes wrong.
    Paggetti J; Moussay E
    Blood; 2016 Jan; 127(4):378-80. PubMed ID: 26823509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.
    Taylor J; Wilmore S; Marriot S; Rogers-Broadway KR; Fell R; Minton AR; Branch T; Ashton-Key M; Coldwell M; Stevenson FK; Forconi F; Steele AJ; Packham G; Yeomans A
    Cell Signal; 2022 Jun; 94():110311. PubMed ID: 35306137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Moyo TK; Wilson CS; Moore DJ; Eischen CM
    Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation.
    Rombout A; Lust S; Offner F; Naessens E; Verhasselt B; Philippé J
    Br J Cancer; 2016 Mar; 114(6):704-12. PubMed ID: 26924423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
    Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM; Cosimo E; Leach MT; Michie AM
    Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
    Yin S; Gambe RG; Sun J; Martinez AZ; Cartun ZJ; Regis FFD; Wan Y; Fan J; Brooks AN; Herman SEM; Ten Hacken E; Taylor-Weiner A; Rassenti LZ; Ghia EM; Kipps TJ; Obeng EA; Cibulskis CL; Neuberg D; Campagna DR; Fleming MD; Ebert BL; Wiestner A; Leshchiner I; DeCaprio JA; Getz G; Reed R; Carrasco RD; Wu CJ; Wang L
    Cancer Cell; 2019 Feb; 35(2):283-296.e5. PubMed ID: 30712845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
    Krysov S; Steele AJ; Coelho V; Linley A; Sanchez Hidalgo M; Carter M; Potter KN; Kennedy B; Duncombe AS; Ashton-Key M; Forconi F; Stevenson FK; Packham G
    Blood; 2014 Nov; 124(20):3101-9. PubMed ID: 25170122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 19. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells.
    Palomba ML; Piersanti K; Ziegler CG; Decker H; Cotari JW; Bantilan K; Rijo I; Gardner JR; Heaney M; Bemis D; Balderas R; Malek SN; Seymour E; Zelenetz AD; van den Brink MR; Altan-Bonnet G
    PLoS One; 2014; 9(1):e79987. PubMed ID: 24489640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.